We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER Shifts Dispute Resolution Program Due to Spike in Appeals
CDER Shifts Dispute Resolution Program Due to Spike in Appeals
An increased number of generic appeals has led CDER to transfer the management of its Formal Dispute Resolution program for sponsors of user fee products from the Office of New Drugs to the Office of Executive Programs, CDER Director Janet Woodcock said in a staff memo.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor